系统性硬化症的纤维化机制和潜在治疗靶点的最新进展

IF 4.4 2区医学 Q1 RHEUMATOLOGY

Seminars in arthritis and rheumatism Pub Date : 2025-08-12 DOI:10.1016/j.semarthrit.2025.152811

Xue Han , Xiuyuan Wang , Junxia Huang, Ji Yang

{"title":"系统性硬化症的纤维化机制和潜在治疗靶点的最新进展","authors":"Xue Han , Xiuyuan Wang , Junxia Huang, Ji Yang","doi":"10.1016/j.semarthrit.2025.152811","DOIUrl":null,"url":null,"abstract":"<div><div>Systemic sclerosis (SSc) is a rare, multisystem autoimmune connective tissue disease characterized by microvascular dysfunction, inflammation, and progressive fibrosis. The pathogenesis of SSc is regulated by both epigenetic and genetic factors. Although the pathogenesis is being explored, treatment options, especially for fibrosis, remain limited. Recent clinical trials have made significant progress in targeting key pathways in fibrosis. This review discusses emerging therapeutic strategies, focusing on targets such as TGF-β signaling, oncostatin M/OSM receptor β axis, lysophosphatidic acid, nuclear receptor superfamily, endocannabinoid system, soluble guanylate cyclase, and mesenchymal stem cells, and highlights the potential of these targets to improve patient outcomes in combination with relevant clinical trials.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"74 ","pages":"Article 152811"},"PeriodicalIF":4.4000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Fibrosis mechanisms and updates in potential therapeutic targets in systemic sclerosis\",\"authors\":\"Xue Han , Xiuyuan Wang , Junxia Huang, Ji Yang\",\"doi\":\"10.1016/j.semarthrit.2025.152811\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Systemic sclerosis (SSc) is a rare, multisystem autoimmune connective tissue disease characterized by microvascular dysfunction, inflammation, and progressive fibrosis. The pathogenesis of SSc is regulated by both epigenetic and genetic factors. Although the pathogenesis is being explored, treatment options, especially for fibrosis, remain limited. Recent clinical trials have made significant progress in targeting key pathways in fibrosis. This review discusses emerging therapeutic strategies, focusing on targets such as TGF-β signaling, oncostatin M/OSM receptor β axis, lysophosphatidic acid, nuclear receptor superfamily, endocannabinoid system, soluble guanylate cyclase, and mesenchymal stem cells, and highlights the potential of these targets to improve patient outcomes in combination with relevant clinical trials.</div></div>\",\"PeriodicalId\":21715,\"journal\":{\"name\":\"Seminars in arthritis and rheumatism\",\"volume\":\"74 \",\"pages\":\"Article 152811\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-08-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in arthritis and rheumatism\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0049017225001829\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in arthritis and rheumatism","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0049017225001829","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

系统性硬化症（SSc）是一种罕见的多系统自身免疫性结缔组织疾病，以微血管功能障碍、炎症和进行性纤维化为特征。SSc的发病机制受表观遗传和遗传因素共同调控。虽然发病机制正在探索中，但治疗方案，特别是纤维化的治疗方案仍然有限。最近的临床试验在靶向纤维化关键通路方面取得了重大进展。本综述讨论了新兴的治疗策略，重点关注TGF-β信号、癌抑制素M/OSM受体β轴、溶血磷脂酸、核受体超家族、内源性大麻素系统、可溶性鸟苷酸环化酶和间充质干细胞等靶点，并结合相关临床试验强调了这些靶点改善患者预后的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Fibrosis mechanisms and updates in potential therapeutic targets in systemic sclerosis

查看原文本刊更多论文

Fibrosis mechanisms and updates in potential therapeutic targets in systemic sclerosis

Systemic sclerosis (SSc) is a rare, multisystem autoimmune connective tissue disease characterized by microvascular dysfunction, inflammation, and progressive fibrosis. The pathogenesis of SSc is regulated by both epigenetic and genetic factors. Although the pathogenesis is being explored, treatment options, especially for fibrosis, remain limited. Recent clinical trials have made significant progress in targeting key pathways in fibrosis. This review discusses emerging therapeutic strategies, focusing on targets such as TGF-β signaling, oncostatin M/OSM receptor β axis, lysophosphatidic acid, nuclear receptor superfamily, endocannabinoid system, soluble guanylate cyclase, and mesenchymal stem cells, and highlights the potential of these targets to improve patient outcomes in combination with relevant clinical trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Seminars in arthritis and rheumatism 医学-风湿病学

CiteScore

9.20

自引率

4.00%

发文量

176

审稿时长

46 days

期刊介绍： Seminars in Arthritis and Rheumatism provides access to the highest-quality clinical, therapeutic and translational research about arthritis, rheumatology and musculoskeletal disorders that affect the joints and connective tissue. Each bimonthly issue includes articles giving you the latest diagnostic criteria, consensus statements, systematic reviews and meta-analyses as well as clinical and translational research studies. Read this journal for the latest groundbreaking research and to gain insights from scientists and clinicians on the management and treatment of musculoskeletal and autoimmune rheumatologic diseases. The journal is of interest to rheumatologists, orthopedic surgeons, internal medicine physicians, immunologists and specialists in bone and mineral metabolism.